Company Encyclopedia
View More
name
Fulgent Genetics
FLGT.US
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
384.68 B
FLGT.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
Health Care ServicesIndustry
Industry Ranking35/82
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-3.80%D
    • Profit Margin-13.62%D
    • Gross Margin42.24%B
  • Growth ScoreB
    • Revenue YoY13.60%B
    • Net Profit YoY73.94%A
    • Total Assets YoY-1.56%D
    • Net Assets YoY-1.25%D
  • Cash ScoreC
    • Cash Flow Margin-734.13%E
    • OCF YoY13.60%B
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreA
    • Gearing Ratio7.72%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx | FLGT Stock News

    Fulgent Genetics has agreed to acquire Bako Diagnostics and StrataDx for approximately $55.5 million. The acquisition will add new anatomic pathology services, proprietary PCR tests, and a national client base. The deal is expected to close in the first half of 2026, subject to regulatory approvals. This acquisition will enhance Fulgent's capabilities in pathology testing, expand its geographic footprint, and leverage AI to improve efficiency and quality. The combined entity aims to provide comprehensive diagnostic services across the U.S.

    StockTitan·
    US
    FLGT
    -1.07%
    StockTitan·
    US
    FLGT
    -1.07%

    Fulgent Genetics Inc. Publishes Transcript of Q3 2025 Earnings Call

    Fulgent Genetics Inc. released the corrected transcript of its Q3 2025 earnings call, held on November 7, 2025. Key executives discussed third-quarter performance, product development, and go-to-market strategies. Analysts from UBS Securities, Piper Sandler & Co., and Raymond James Financial participated. The CEO highlighted operational progress and provided financial results and forward-looking guidance, noting risks and uncertainties. The transcript is available online, with a disclaimer that the content is AI-generated for informational purposes only.

    Reuters·
    US
    FLGT
    -1.07%
    Reuters·
    US
    FLGT
    -1.07%

    Insider Selling: Fulgent Genetics (NASDAQ:FLGT) Insider Sells 1,075 Shares of Stock

    Fulgent Genetics insider Hanlin Gao sold 1,075 shares at $28.33 each, totaling $30,454.75. Post-sale, Gao owns 952,890 shares valued at $26,995,373.70, marking a 0.11% position decrease. Recent trades include selling 943 shares at $29.57 and 535 shares at $30.47. Fulgent's stock opened at $28.55, with a market cap of $882.57 million. Analysts have mixed ratings, with a target price of $32.00. Institutional investors hold 48.06% of shares.

    Market Beat·
    US
    FLGT
    -1.07%
    Market Beat·
    US
    FLGT
    -1.07%

    Fulgent Genetics Chief Scientific Officer Hanlin Gao Sells Common Shares

    Hanlin Gao, Chief Scientific Officer of Fulgent Genetics Inc., has sold common shares of the company. The transaction details were filed with the U.S. Securities and Exchange Commission on December 03, 2025. This information is provided by Public Technologies and is for informational purposes only.

    Reuters·
    US
    FLGT
    -1.07%
    Reuters·
    US
    FLGT
    -1.07%

    Pres Xie Surrenders 1,198 Of Fulgent Genetics Inc [FLGT]

    Xie Jian James, President of Fulgent Genetics Inc, surrendered 1,198 shares back to the company to cover option exercise costs and/or tax liabilities, as disclosed in a Form 4 filed with the SEC on December 1, 2025. The transaction was valued at $35,424, with ending holdings of 558,705 shares.

    Reuters·
    US
    FLGT
    -1.07%
    Reuters·
    US
    FLGT
    -1.07%
    © 2025 Longbridge｜Disclaimer